Clinical Scorecard: IHS, ACP Differ on Migraine Treatment

At a Glance

Key Highlights

• IHS recommends oral triptans as first-line acute therapy; ACP recommends triptan combined with NSAID or acetaminophen.
• CGRP-targeting therapies may provide faster preventive response but are costly and recommended by ACP only after oral preventive failure.
• Triptans contraindicated in cardiovascular disease; gepants avoid medication overuse headache and useful in triptan-intolerant patients.

Guideline-Based Recommendations

Diagnosis

• Assess headache frequency and prior treatment response to classify episodic or chronic migraine.

Management

• IHS: Use oral triptans first-line for acute treatment; ACP: Use triptan plus NSAID or acetaminophen.
• Consider NSAIDs (ibuprofen 400 mg, naproxen 500 mg) as effective acute options.
• Use gepants for patients at risk of medication overuse headache or who cannot tolerate triptans.
• Preventive therapy choice individualized based on patient factors including reproductive status, cardiovascular risk, and prior response.
• CGRP-targeting monoclonal antibodies or oral antagonists may be used for prevention, with ACP reserving them for oral preventive failures.

Monitoring & Follow-up

• Monitor for medication overuse headache with frequent acute therapy use except with gepants.
• Assess preventive therapy effectiveness by reduction in monthly migraine days (≥50% for episodic, ≥30% for chronic).
• Evaluate adverse effects and treatment discontinuation rates, especially with oral preventive medications.

Risks

• Triptans contraindicated in patients with cardiovascular disease.
• Frequent use of most acute therapies (except gepants) can cause medication overuse headache.
• High cost and limited long-term safety data for CGRP-targeting therapies.

Patient & Prescribing Data

Patients with episodic or chronic migraine, including those with prior preventive treatment failure

Erenumab showed 56% achieving ≥50% reduction in monthly migraine days vs 17% with oral preventives; lower discontinuation due to adverse effects (3% vs 23%).

Clinical Best Practices

• Tailor treatment to patient-specific factors including headache pattern, comorbidities, reproductive goals, and risk factors.
• Address modifiable risk factors such as medication overuse, sleep hygiene, and migraine triggers.
• Avoid polypharmacy and consider cost-effectiveness when selecting preventive therapies.
• Use gepants for patients at risk of medication overuse headache or with contraindications to triptans.

References

• Annals of Internal Medicine Grand Rounds on Migraine Treatment